CD274 and neoplasm: The response rate was related to tumor PD-L1 expression; 28.4% for patients with tumor PD-L1 expression ≥5%, 23.8% for patients with tumor PD-L1 expression ≥1% and 16.1% for patients with low PD-L1 expression (<1%).